title: Avastin for breast cancer, 2005-2011: requiescat in pacem?
authors.forename: Harold J
authors.initials: HJ
authors.lastname: Burstein
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000191:economics; D002277:Carcinoma / Q000188:drug therapy* / Q000191:economics; D002986:Clinical Trials as Topic; D003627:Data Interpretation, Statistical; D034462:Dissent and Disputes; D017277:Drug Approval / Q000331:legislation & jurisprudence / Q000379:methods; D005260:Female; D006801:Humans; D008402:Mass Media; D008495:Medical Oncology / Q000331:legislation & jurisprudence* / Q000639:trends*; D017410:Practice Guidelines as Topic; D011358:Product Surveillance, Postmarketing; D056737:Safety-Based Drug Withdrawals; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab